Follow
2cureX AB
Nasdaq First North Sweden (Sweden)
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency mainly for cancer patients. It is involved in developing product namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and kidney cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Media
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
2CUREX
SE0010468124
Nasdaq First North Sweden
Sweden (SE)
Details of share in 2cureX AB with ticker 2CUREX
Status
Active
Order book id
Amount of instruments
12 420 000
Par value
Market cap
Currency
SEK
Segment
First North
First trading date
24 Oct 2017
Terms
Today, October 13, 2017, the subscription period of 2cureX AB's ("2cureX") new share issue will begin prior to scheduled listing on Nasdaq Stockholm First North. Subscription period expires on 27 October 2017. In the case of a fully subscribed new share issue, 2cureX is totaled approximately SEK 18.3 million before issue costs. Emission liquidity is intended to fund all preparatory activities for market launch of IndiTreat ™, which includes CE marking and ISO certification, sales organization building, revenue recognition strategies and establishment of additional validation sites in Germany, England and France. 2cureX has agreed in advance in writing about subscriptions of a total of approximately SEK 9.2 million, corresponding to approximately 50 percent of the issue fee. Memorandum, teaser and application for subscription of shares are available at 2cureX's (www.2curex.com ) and Sedermera Fondkommission ( www.sedermera.se ) and websites. In addition, there is the possibility to subscribe for shares with Bank ID on the Sedermera Fund Commission website. Sedermera Fondkommission is 2cureX's financial adviser in connection with the rights issue and the planned listing on Nasdaq Stockholm First North.
Type
Price
Pre-money valuation
Time
Files
IPO
7.80 SEK
62.4M SEK
13 Oct - 27 Oct 2017
IPO in 2cureX AB
Type
Price
Pre-money valuation
Time
Files
Rights issue
11.95 SEK
123.68M SEK
09 May - 23 May 2019
Share issue in 2cureX AB
Type
Price
Pre-money valuation
Time
Files
Targeted issue
16.50 SEK
204.9M SEK
06 Jul 2020
Share issue in 2cureX AB
Type
Ticker
ISIN
Market
OPTION
WARRANT TO 1
Nasdaq First North Sweden
Sweden (SE)
Details of option in 2cureX AB with ticker WARRANT TO 1
Status
Inactive
Order book id
Amount of instruments
2 455 000
Market cap
Currency
SEK
First trading date
Terms
Each warrant of series TO1 will give the holder the right to subscribe for one (1) new share at a subscription price corresponding to 70 percent of the average volume-weighted share price according to Nasdaq First North Growth Market’s official price statistics during the period from April 9, 2021 to April 22, 2021.
Type
Price
Pre-money valuation
Time
Files
Exercise
0.10-28.88 SEK
26 Apr - 07 May 2021
Option exercise terms for WARRANT TO 1
People
Number of Employees
11 people
Ole Thastrup
CEO
Povl-Andre Bendz
Chairman of the board
Ole Thastrup
Board member
Jørgen Drejer
Board member
Juan Farré
Board member
Simon Hesse Hoffmann
Board member
Timm Jessen
Board member
Ulrich Spengler
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Box 159
Zip code
261 22
City/district
Landskrona
Country
Sweden (SE)
Registration number
559128-0077
LEI code
549300SFOL75WIYF2O80
First trade date
24 Oct 2017
Registration date
05 Oct 2017
Short name
2cureX

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date